Sonnet Biotherapeutics Holdings Inc (SONN)

$5.54 -0.36 (-6.10%)
Market Cap 40.28M
Revenue (ttm) 20,000.00
Net Income (ttm) -7.44M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -37,200.00%
Debt to Equity Ratio 0.00
Volume 3,099,600
Avg Vol 2,664,800
Day's Range N/A - N/A
Shares Out 6.83M
Stochastic %K 81%
Beta 1.21
Analysts Sell
Price Target $20.00

Company Profile

Sonnet BioTherapeutics Holdings, Inc., a biotechnology company, owns a platform for biologic medicines of single or bifunctional action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead product candidate is SON-1010, a fully human single-chain version of interleukin 12 for the treatment of solid tumor indications, including ovarian cance...

Industry: Biotechnology
Sector: Healthcare
Phone: 609 375 2227
Address:
100 Overlook Center, Suite 102, Princeton, United States
GSP
GSP Sep. 15 at 10:16 PM
$NNE $SMR $SONN $SPY $UAMY
0 · Reply
Joebull83
Joebull83 Sep. 15 at 9:41 PM
$SONN 🤓
0 · Reply
CUBAN_CIGAR
CUBAN_CIGAR Sep. 15 at 8:49 PM
$SONN ***DO YOUR DD, WE DID OURS, 1,000%+ GAINER HERE LIKELY, ((((HYPECOIN))))*** we covered our shorts for profit today did our DD, bought some....GL ALL
0 · Reply
CUBAN_CIGAR
CUBAN_CIGAR Sep. 15 at 8:34 PM
$SONN **WE BOUGHT SOME BEFORE CLOSE** adding on strength tomorrow, not a big dip after up 50% FRIDAY
0 · Reply
Jackie_Treehorn
Jackie_Treehorn Sep. 15 at 5:16 PM
$SONN nice rebound!
0 · Reply
CometaMan
CometaMan Sep. 15 at 5:03 PM
Taking my nice profit from $SONN and buying me some more $LIMN Monday kick back sale day 1.84s!
0 · Reply
Camelinvesting
Camelinvesting Sep. 15 at 4:41 PM
$SONN on watch 🔥 Interesting chart 📈
0 · Reply
maciehudson
maciehudson Sep. 15 at 3:23 PM
$SONN NXXT command center UOS turning assets into smart nodes visibility control monetization that scales with every deployment
0 · Reply
jbear7912
jbear7912 Sep. 15 at 3:23 PM
$SONN Guys check $ORIS Looks healthy!!
0 · Reply
CashCows_
CashCows_ Sep. 15 at 3:17 PM
$SONN how much did you lose ? I warned you! lol 😂 You know who made money in this case your broker! Short allocation are not cheap. lol
0 · Reply
Latest News on SONN
Sonnet Releases Virtual Investor "What This Means" Segment

Aug 11, 2025, 9:15 AM EDT - 5 weeks ago

Sonnet Releases Virtual Investor "What This Means" Segment

Sonnet BioTherapeutics Expands Clinical Evaluation of SON-1010 Dose Escalation with Atezolizumab in Ovarian Cancer

Aug 4, 2025, 8:40 AM EDT - 6 weeks ago

Sonnet BioTherapeutics Expands Clinical Evaluation of SON-1010 Dose Escalation with Atezolizumab in Ovarian Cancer

Why Is Sonnet BioTherapeutics Stock Trading Higher On Monday?

Jul 14, 2025, 11:30 AM EDT - 2 months ago

Why Is Sonnet BioTherapeutics Stock Trading Higher On Monday?

Sonnet BioTherapeutics, Inc. Announces $888 Million Business Combination to Launch a HYPE Cryptocurrency Treasury Reserve Strategy

Jul 14, 2025, 6:00 AM EDT - 2 months ago

Sonnet BioTherapeutics, Inc. Announces $888 Million Business Combination to Launch a HYPE Cryptocurrency Treasury Reserve Strategy

Sonnet Chief Medical Officer, Richard Kenney, M.D., to Present at the 6th Annual Cytokine-Based Drug Development Summit

May 1, 2025, 9:00 AM EDT - 4 months ago

Sonnet Chief Medical Officer, Richard Kenney, M.D., to Present at the 6th Annual Cytokine-Based Drug Development Summit

Sonnet's SON-1010 Demonstrates a Strong Safety Profile in Combination with Atezolizumab for Treatment of Platinum-Resistant Ovarian Cancer, Including a Partial Response at the Highest Dose

Apr 4, 2025, 9:00 AM EDT - 5 months ago

Sonnet's SON-1010 Demonstrates a Strong Safety Profile in Combination with Atezolizumab for Treatment of Platinum-Resistant Ovarian Cancer, Including a Partial Response at the Highest Dose

Sonnet Announces Release of Corporate Update Video

Apr 1, 2025, 4:15 PM EDT - 5 months ago

Sonnet Announces Release of Corporate Update Video

Sonnet Announces the Passing of Founder and CEO Pankaj Mohan, Ph.D.

Apr 1, 2025, 7:30 AM EDT - 5 months ago

Sonnet Announces the Passing of Founder and CEO Pankaj Mohan, Ph.D.

Sonnet BioTherapeutics Successfully Completes First Safety Review of SON-1010 in Combination with Trabectedin in Certain Sarcomas

Mar 26, 2025, 9:05 AM EDT - 6 months ago

Sonnet BioTherapeutics Successfully Completes First Safety Review of SON-1010 in Combination with Trabectedin in Certain Sarcomas

Sonnet BioTherapeutics Receives Notice of Allowance for U.S. Patent Covering Composition of Matter of Specific Amino Acid Substitutions of its IL-18 Binding Protein Resistant Variant Protein

Mar 19, 2025, 8:50 AM EDT - 6 months ago

Sonnet BioTherapeutics Receives Notice of Allowance for U.S. Patent Covering Composition of Matter of Specific Amino Acid Substitutions of its IL-18 Binding Protein Resistant Variant Protein

Sonnet BioTherapeutics Holdings, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

Mar 11, 2025, 8:45 AM EDT - 6 months ago

Sonnet BioTherapeutics Holdings, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

Sonnet BioTherapeutics Presents Compilation of Data Highlighting the Potential of SON-1010 as a Monotherapy or a Combination Therapy to Improve the Treatment of Solid Tumors

Feb 26, 2025, 9:00 AM EST - 7 months ago

Sonnet BioTherapeutics Presents Compilation of Data Highlighting the Potential of SON-1010 as a Monotherapy or a Combination Therapy to Improve the Treatment of Solid Tumors

Sonnet BioTherapeutics Announces That Its Proprietary Antibody Drug Conjugate (ADC) Platform is Available for Drug Discovery Partnerships with Potential for Producing Multiple Pipeline Drug Candidates

Feb 19, 2025, 8:35 AM EST - 7 months ago

Sonnet BioTherapeutics Announces That Its Proprietary Antibody Drug Conjugate (ADC) Platform is Available for Drug Discovery Partnerships with Potential for Producing Multiple Pipeline Drug Candidates

Sonnet BioTherapeutics Selected for Poster Presentation at the 2025 AACR IO Conference

Feb 18, 2025, 9:15 AM EST - 7 months ago

Sonnet BioTherapeutics Selected for Poster Presentation at the 2025 AACR IO Conference

Sonnet BioTherapeutics Appoints Stephen McAndrew, Ph.D. as Chief Business Officer

Feb 13, 2025, 8:30 AM EST - 7 months ago

Sonnet BioTherapeutics Appoints Stephen McAndrew, Ph.D. as Chief Business Officer

Sonnet BioTherapeutics Provides Fiscal Year 2025 First Quarter Business and Earnings Update

Feb 13, 2025, 8:00 AM EST - 7 months ago

Sonnet BioTherapeutics Provides Fiscal Year 2025 First Quarter Business and Earnings Update

Sonnet BioTherapeutics Further Expands Global Intellectual Property Portfolio with Issuance of EU Patent for FHAB® Platform Technology

Jan 28, 2025, 9:05 AM EST - 8 months ago

Sonnet BioTherapeutics Further Expands Global Intellectual Property Portfolio with Issuance of EU Patent for FHAB® Platform Technology

Sonnet BioTherapeutics to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar

Jan 22, 2025, 8:35 AM EST - 8 months ago

Sonnet BioTherapeutics to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar

Sonnet BioTherapeutics Expands Phase 1 SB101 Trial to Evaluate Combination of SON-1010 with Trabectedin in Certain Sarcomas

Jan 21, 2025, 9:05 AM EST - 8 months ago

Sonnet BioTherapeutics Expands Phase 1 SB101 Trial to Evaluate Combination of SON-1010 with Trabectedin in Certain Sarcomas

Sonnet BioTherapeutics Announces Release of the Next CEO Corner Segment

Dec 23, 2024, 9:20 AM EST - 9 months ago

Sonnet BioTherapeutics Announces Release of the Next CEO Corner Segment

Sonnet BioTherapeutics Reports Fiscal Year 2024 Financial Results and Provides Corporate Update

Dec 17, 2024, 8:50 AM EST - 9 months ago

Sonnet BioTherapeutics Reports Fiscal Year 2024 Financial Results and Provides Corporate Update

Sonnet BioTherapeutics Announces $3.9 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules

Dec 9, 2024, 3:42 PM EST - 10 months ago

Sonnet BioTherapeutics Announces $3.9 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules

Sonnet BioTherapeutics Announces Topline Safety Data Following Successful Completion of SON-1010 Monotherapy Dose Escalation in Phase 1 SB101 Trial

Dec 9, 2024, 8:45 AM EST - 10 months ago

Sonnet BioTherapeutics Announces Topline Safety Data Following Successful Completion of SON-1010 Monotherapy Dose Escalation in Phase 1 SB101 Trial

Sonnet BioTherapeutics Announces Publication Detailing the Discovery and Development of SON-1010, an Albumin-Binding IL-12 Fusion Protein, Demonstrating Its Mechanism of Action

Dec 4, 2024, 9:20 AM EST - 10 months ago

Sonnet BioTherapeutics Announces Publication Detailing the Discovery and Development of SON-1010, an Albumin-Binding IL-12 Fusion Protein, Demonstrating Its Mechanism of Action

Sonnet BioTherapeutics Releases Virtual Investor ‘”What this Means” Segment

Nov 12, 2024, 9:15 AM EST - 10 months ago

Sonnet BioTherapeutics Releases Virtual Investor ‘”What this Means” Segment

Sonnet BioTherapeutics Announces Pricing of $5.0 Million Underwritten Public Offering Priced At-The-Market Under Nasdaq Rules

Nov 6, 2024, 1:20 PM EST - 11 months ago

Sonnet BioTherapeutics Announces Pricing of $5.0 Million Underwritten Public Offering Priced At-The-Market Under Nasdaq Rules

Sonnet BioTherapeutics Announces Issuance of U.S. Patent Covering a Variant IL-18 Incorporated into Two Novel Immunotherapeutic Drug Candidates

Nov 6, 2024, 8:30 AM EST - 11 months ago

Sonnet BioTherapeutics Announces Issuance of U.S. Patent Covering a Variant IL-18 Incorporated into Two Novel Immunotherapeutic Drug Candidates

Sonnet BioTherapeutics Inc. Regains Compliance with Nasdaq

Oct 17, 2024, 8:45 AM EDT - 11 months ago

Sonnet BioTherapeutics Inc. Regains Compliance with Nasdaq

Sonnet BioTherapeutics Inc. Enters into Licensing Agreement with Alkem Laboratories Limited to Develop and Commercialize SON-080 for Diabetic Peripheral Neuropathy (DPN) in India

Oct 9, 2024, 8:45 AM EDT - 1 year ago

Sonnet BioTherapeutics Inc. Enters into Licensing Agreement with Alkem Laboratories Limited to Develop and Commercialize SON-080 for Diabetic Peripheral Neuropathy (DPN) in India

Sonnet BioTherapeutics to Receive Non-Dilutive Funding Through New Jersey Tax Certificate Transfer and Australia R&D Tax Incentive Programs

Oct 4, 2024, 8:30 AM EDT - 1 year ago

Sonnet BioTherapeutics to Receive Non-Dilutive Funding Through New Jersey Tax Certificate Transfer and Australia R&D Tax Incentive Programs

Sonnet BioTherapeutics Announces Launch of CEO Corner Platform

Sep 30, 2024, 9:00 AM EDT - 1 year ago

Sonnet BioTherapeutics Announces Launch of CEO Corner Platform

Sonnet BioTherapeutics Announces 1-for-8 Reverse Stock Split

Sep 25, 2024, 8:30 AM EDT - 1 year ago

Sonnet BioTherapeutics Announces 1-for-8 Reverse Stock Split

Sonnet BioTherapeutics Completes Enrollment in Phase 1 Study of SON-1010 (IL12-FHAB) as a Monotherapy (SB101) for the Treatment of Solid Tumors

Sep 18, 2024, 8:30 AM EDT - 1 year ago

Sonnet BioTherapeutics Completes Enrollment in Phase 1 Study of SON-1010 (IL12-FHAB) as a Monotherapy (SB101) for the Treatment of Solid Tumors

Sonnet BioTherapeutics to Participate in the Virtual Investor Closing Bell Series

Sep 4, 2024, 9:15 AM EDT - 1 year ago

Sonnet BioTherapeutics to Participate in the Virtual Investor Closing Bell Series

Sonnet BioTherapeutics Enters into Clinical Collaboration Agreement to Commence Investigator-Initiated and Funded Phase 1/2a Study of SON-1210 in Combination with Chemotherapy for the Treatment of Pancreatic Cancer

Aug 19, 2024, 8:45 AM EDT - 1 year ago

Sonnet BioTherapeutics Enters into Clinical Collaboration Agreement to Commence Investigator-Initiated and Funded Phase 1/2a Study of SON-1210 in Combination with Chemotherapy for the Treatment of Pancreatic Cancer

Sonnet BioTherapeutics Reports Third Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update

Aug 14, 2024, 8:35 AM EDT - 1 year ago

Sonnet BioTherapeutics Reports Third Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update

Sonnet BioTherapeutics (NASDAQ:SONN) Participates in Virtual Investor "What This Means" Segment Hosted by JTC Team

Jul 24, 2024, 3:00 PM EDT - 1 year ago

Sonnet BioTherapeutics (NASDAQ:SONN) Participates in Virtual Investor "What This Means" Segment Hosted by JTC Team

Sonnet BioTherapeutics Reports Encouraging Data from Phase 1b/2a Clinical Trial of SON-080 in Chemotherapy-Induced Peripheral Neuropathy (CIPN) That Support Advancement into Phase 2 Study

Jul 24, 2024, 8:30 AM EDT - 1 year ago

Sonnet BioTherapeutics Reports Encouraging Data from Phase 1b/2a Clinical Trial of SON-080 in Chemotherapy-Induced Peripheral Neuropathy (CIPN) That Support Advancement into Phase 2 Study

Sonnet BioTherapeutics to Present SB221 as a Trial in Progress at the ASCO 2024 Annual Meeting

May 28, 2024, 8:00 AM EDT - 1 year ago

Sonnet BioTherapeutics to Present SB221 as a Trial in Progress at the ASCO 2024 Annual Meeting

Sonnet BioTherapeutics Announces Updated Clinical Data for SON-1010 as Monotherapy or Combined with an anti-PD-L1, along with an Increase in the Dose-Escalation Target

May 20, 2024, 9:15 AM EDT - 1 year ago

Sonnet BioTherapeutics Announces Updated Clinical Data for SON-1010 as Monotherapy or Combined with an anti-PD-L1, along with an Increase in the Dose-Escalation Target

Sonnet BioTherapeutics Provides Fiscal Year 2024 Second Quarter and Year-to-Date Business and Earnings Update

May 14, 2024, 4:15 PM EDT - 1 year ago

Sonnet BioTherapeutics Provides Fiscal Year 2024 Second Quarter and Year-to-Date Business and Earnings Update

Sonnet BioTherapeutics Announces Participation in the EF Hutton Annual Global Conference

May 6, 2024, 7:00 AM EDT - 1 year ago

Sonnet BioTherapeutics Announces Participation in the EF Hutton Annual Global Conference

Sonnet BioTherapeutics to Present Preclinical Data on SON-080 for Chemotherapy-Induced Peripheral Neuropathy (CIPN) at the AACR 2024 Annual Meeting

Mar 19, 2024, 7:30 AM EDT - 1 year ago

Sonnet BioTherapeutics to Present Preclinical Data on SON-080 for Chemotherapy-Induced Peripheral Neuropathy (CIPN) at the AACR 2024 Annual Meeting

Sonnet BioTherapeutics Announces Early Safety Data from the Company's Phase 1b/2a Clinical Trial of SON-080 in Chemotherapy-Induced Peripheral Neuropathy (CIPN) Met the Study's Initial Pre-Specified Objective

Mar 11, 2024, 7:30 AM EDT - 1 year ago

Sonnet BioTherapeutics Announces Early Safety Data from the Company's Phase 1b/2a Clinical Trial of SON-080 in Chemotherapy-Induced Peripheral Neuropathy (CIPN) Met the Study's Initial Pre-Specified Objective

Sonnet BioTherapeutics Announces a Publication Demonstrating Safety and Tolerability of SON-1010 in Healthy Volunteers

Feb 29, 2024, 4:05 PM EST - 1 year ago

Sonnet BioTherapeutics Announces a Publication Demonstrating Safety and Tolerability of SON-1010 in Healthy Volunteers

Sonnet BioTherapeutics Provides Fiscal Year 2024 First Quarter Business and Earnings Update

Feb 14, 2024, 7:30 AM EST - 1 year ago

Sonnet BioTherapeutics Provides Fiscal Year 2024 First Quarter Business and Earnings Update

Sonnet BioTherapeutics Announces Publication Demonstrating Suitability of SON-1210, the First Albumin-binding Bifunctional IL-12/IL-15 Fusion Protein, for Solid Tumor Immunotherapy

Dec 21, 2023, 8:00 AM EST - 1 year ago

Sonnet BioTherapeutics Announces Publication Demonstrating Suitability of SON-1210, the First Albumin-binding Bifunctional IL-12/IL-15 Fusion Protein, for Solid Tumor Immunotherapy

Sonnet BioTherapeutics Provides Fiscal Year 2023 Business and Financial Update

Dec 14, 2023, 4:15 PM EST - 1 year ago

Sonnet BioTherapeutics Provides Fiscal Year 2023 Business and Financial Update

Sonnet BioTherapeutics Provides Fiscal Year 2023 Business Overview

Oct 31, 2023, 7:30 AM EDT - 2 years ago

Sonnet BioTherapeutics Provides Fiscal Year 2023 Business Overview

GSP
GSP Sep. 15 at 10:16 PM
$NNE $SMR $SONN $SPY $UAMY
0 · Reply
Joebull83
Joebull83 Sep. 15 at 9:41 PM
$SONN 🤓
0 · Reply
CUBAN_CIGAR
CUBAN_CIGAR Sep. 15 at 8:49 PM
$SONN ***DO YOUR DD, WE DID OURS, 1,000%+ GAINER HERE LIKELY, ((((HYPECOIN))))*** we covered our shorts for profit today did our DD, bought some....GL ALL
0 · Reply
CUBAN_CIGAR
CUBAN_CIGAR Sep. 15 at 8:34 PM
$SONN **WE BOUGHT SOME BEFORE CLOSE** adding on strength tomorrow, not a big dip after up 50% FRIDAY
0 · Reply
Jackie_Treehorn
Jackie_Treehorn Sep. 15 at 5:16 PM
$SONN nice rebound!
0 · Reply
CometaMan
CometaMan Sep. 15 at 5:03 PM
Taking my nice profit from $SONN and buying me some more $LIMN Monday kick back sale day 1.84s!
0 · Reply
Camelinvesting
Camelinvesting Sep. 15 at 4:41 PM
$SONN on watch 🔥 Interesting chart 📈
0 · Reply
maciehudson
maciehudson Sep. 15 at 3:23 PM
$SONN NXXT command center UOS turning assets into smart nodes visibility control monetization that scales with every deployment
0 · Reply
jbear7912
jbear7912 Sep. 15 at 3:23 PM
$SONN Guys check $ORIS Looks healthy!!
0 · Reply
CashCows_
CashCows_ Sep. 15 at 3:17 PM
$SONN how much did you lose ? I warned you! lol 😂 You know who made money in this case your broker! Short allocation are not cheap. lol
0 · Reply
CashCows_
CashCows_ Sep. 15 at 3:12 PM
$SONN, you should short more! It's a fake pump like you said earlier
0 · Reply
Winning_calls
Winning_calls Sep. 15 at 3:05 PM
$SONN join the team🤞🤞get
0 · Reply
slickinvest
slickinvest Sep. 15 at 2:54 PM
$SONN maybe some kind of news Coming out soon
0 · Reply
Game_Day
Game_Day Sep. 15 at 2:53 PM
$SONN may get halted
0 · Reply
Bullbear1010101
Bullbear1010101 Sep. 15 at 2:52 PM
$SONN 6.2!
0 · Reply
Mg_1970
Mg_1970 Sep. 15 at 2:52 PM
$SONN Sold 2500 at 6.25
0 · Reply
CUBAN_CIGAR
CUBAN_CIGAR Sep. 15 at 2:49 PM
$SONN ***WTF*** glad I covered my shorts wow
2 · Reply
EC100
EC100 Sep. 15 at 2:49 PM
$SONN 6.50 next
0 · Reply
Alidrisi
Alidrisi Sep. 15 at 2:49 PM
$SONN
0 · Reply
_www_larval_com_
_www_larval_com_ Sep. 15 at 2:48 PM
$SONN has shot 8% higher to 0% (~1Mv) a moment ago, follow for more volatility.
1 · Reply
dinoz1001
dinoz1001 Sep. 15 at 2:48 PM
$SONN Nice move
0 · Reply
CometaMan
CometaMan Sep. 15 at 2:29 PM
Got my cups filled and it's overflowing $SONN and soon $LIMN will do the same! Ecclesiastes 5:19 As for every man to whom God has given riches and wealth, and given him power to eat of it, to receive his heritage and rejoice in his labor—this is the gift of God.
0 · Reply